Pharmaceutical targeting Th2-mediated immunity enhances immunotherapy response in breast cancer.
Yuru ChenJiazheng SunYachan LuoJiazhou LiuXiaoyu WangRui FengJing HuangHuimin DuQin LiJinxiang TanGuosheng RenXiaoyi WangHongzhong LiPublished in: Journal of translational medicine (2022)
Our findings demonstrate that pharmaceutical inhibition of Th2 cell function improves ICB response via remodeling immune landscape of TME, which illustrates a promising combinatorial immunotherapy.